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Abstract
Background: Epithelial ovarian cancer (EOC) is one of the leading causes of cancer deaths in women worldwide.
Adrenomedullin (AM) is a multifunctional peptide which presents in various kinds of tumors.
Methods: In this study, we characterized the expression and function of AM in epithelial ovarian cancer using
immunohistochemistry staining. Exogenous AM and small interfering RNA (siRNA) specific for AM receptor CRLR
were treated to EOC cell line HO8910. Wound healing assay and flow cytometry were used to measure the
migration ability and expression of integrin a5 of HO8910 cells after above treatments. Western blot was used to
examine the phosphorylation of FAK and paxillin.
Results: We found that patients with high AM expression showed a higher incidence of metastasis, larger residual
size of tumors after cytoreduction and shorter disease-free and overall survival time. Exogenous AM induced
ovarian cancer cell migration in time- and dose- dependent manners. AM upregulated the expression of integrin
a5 and phosphorylation of FAK, paxillin as well.
Conclusions: Our results suggested that AM contributed to the progression of EOC and had additional roles in
EOC cell migration by activating the integrin a5b1 signaling pathway. Therefore, we presumed that AM could be a
potential molecular therapeutic target for ovarian carcinoma.
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Background
Epithelial ovarian cancer (EOC) is the sixth most com-
mon cancer and the fifth leading cause of cancer mor-
tality in women worldwide [1]. This lethal gynecological
malignancy is commonly diagnosed at a late stage due
to the silent early stage and easily metastasis. Many
advances took place in the pathological study and in
understanding the mechanisms involved in EOC pro-
gression, details still need further investigations [2,3].
Therefore, this is an urgent need of more effective and
new molecular targeted therapies for EOC.
Adrenomedullin (AM) is a 52-amino-acid peptide first
isolated from human pheochromocytoma [4]. It belongs
to a family of peptides with calcitonin gene-related pep-
tide (CGRP) and Amylin [5]. AM was identified as a
major regulator of carcinogenesis and tumor progres-
sion, and autocrine loop of AM was targeted as new
strategies against human cancers [6-8]. AM gene expres-
sion was proved to be associated with histological grade
and poor prognosis of ovarian cancer [9]. The expres-
sion of its receptor calcitonin receptor-like receptor
CRLR together with modulation factors RAMP2/
RAMP3 were also found in EOC tissues and OVCAR3
cells [10,11]. Our previous study had found that AM
was autocrined in EOC cell line CAOV3 by bFGF sti-
mulation [12].Thus we supposed that AM may play an
important role in EOC progression.
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Integrins are family of transmembrane proteins, which
are composed of 2 subunits as a- and b- formed hetero-
dimer, and work as receptors of extracellular matrix
(ECM) [13]. Integrins received and transmitted the sig-
nal from ECM into cells and modified various function
of cells including shape, motility, and involved in EOC
metastasis [14,15]. It was well accepted that integrin a5
specifically bound to integrin b1 to form specific recep-
tor for fibronectin (FN). Activated integrin a5b1 could
activate the focal adhension kinase (FAK) and Src,
which consequently promoted cancer cells migration
and invasion via activating various skeleton proteins,
such as paxillin. It was reported that overexpression of
integrin a5b1 predicted poor prognosis for EOCs [16].
And integrin a5b1 promoted ovarian cancer cells inva-
sion by directly activating c-Met followed by FAK acti-
vation [17].
In this study, we evaluated AM expression in EOC tis-
sues by immunohistological staining to analyze possible
correlations between AM expression and the clinical
determination of FIGO staging, differentiation, and
prognosis. We further probed the biological features of
AM by assaying cell migration and potential mechanism
underlying this.
Methods
Cell culture and reagents
EOC cell line HO8910 cells were maintained in RPMI
1640 medium with 10% fetal bovine serum (Thermo
Scientific Hyclone, USA), supplemented with 100 units/
ml penicillin and 100 units/ml streptomycin (Sigma,
USA) and maintained at 37°C with 5% CO2. When con-
fluent, cells were treated with 100 nM AM (Phoenix
Pharmaceuticals, USA). Cells were pretreated by 1 nM
AM22-52 (Phoenix Pharmaceuticals, USA), or by 5 μg/
ml the anti-integrin a5b1 monoclonal blocking antibody
(mAb) (BD Biosciences, USA) 1 h followed by AM.
Tissue samples
For immunohistochemical analysis, EOCs (n = 96) were
collected from surgical specimens originating from the
First Affiliated Hospital of China Medical University
between 2000 and 2008. Clinical data were obtained
from clinical databases and tumors were staged accord-
ing to International Federation of Gynecology and
Obstetrics (FIGO) guidelines. There were 82 cases that
had complete follow-up records.
Immunohistochemical staining and evaluation
All paraffin sections were deparaffinized and rehydrated.
The sections were hematoxylin-and-eosin (HE) stained
to confirm histological diagnosis by two pathologists
(Yuan Miao and Xiaoli Zhang) according to the World
Health Organization (WHO) classifications. Sections
were subjected to antigen retrieval by heating in Tris-
EDTA buffer at pH 8.0 in an autoclave sterilizer for 2
min. A blocking solution consisting of 3% H2O2 and 5%
bovine serum albumin was used to block endogenous
peroxidase activity and non-specific binding. The sec-
tions were incubated with goat anti-AM antibody (10
μg/ml; R&D, USA) overnight at 4°C. On the next day,
the sections were treated with the secondary antibody
and SP complex (streptavidin-peroxidase) for 40 min
(Maixin Biotechnology, Fujian, China). Binding sites
were visualized with 3,3’-diainobenzidine (DAB) after 1
min incubation (Maixin Biotechnology, Fujian, China).
After counterstaining with Mayer’s hematoxylin, the sec-
tions were dehydrated and mounted. For the negative
control, phosphate-buffered saline (PBS) was used
instead of the primary antibody.
We evaluated the cytoplasmic and membrane distribu-
tion of AM protein for statistical analysis in EOCs. One
hundred cells were randomly selected and AM distribu-
tion was manually counted from 5 representative 400 ×
fields of each section by two independent observers
(Yuan Miao and Boya Deng) in a blinded study. The per-
centage of cells positive for AM cytoplasmic and mem-
brane expression was graded and counted as follows: (0 =
negative; 1 = 1-50%; 2 = 50-74%; 3 ≥ 75%). The staining
intensity score was graded as follows for cytoplasmic
expression (1 = weak; 2 = intermediate; and 3 = strong).
The scores for AM positivity and staining intensity were
multiplied to obtain a final score, which determines AM
expression as (- = 0; + = 1-2; ++ = 3-4; +++ = 6-9).
Western blot
Cells were washed twice with ice-cold PBS, collected
and homogenized on ice in 10 volumes (w/v) of lysis
buffer containing 20 mM Tris-HCl, 1 mM EDTA, 50
mM NaF, 50 mM NaCl, 1 mM Na3VO4, 1% Triton X-
100, AND 1 mM PMSF. The homogenate was centri-
fuged at 15,000 rpm for 30 min at 4°C. The supernatant
was collected and protein content was determined using
the BCA assay (Beyotime Institute of Biotechnology,
Jiangsu, China). Protein was separated by 10% SDS-
PAGE and then transferred to PVDF blotting mem-
branes, which were then blocked for 2 h in 5% defatted
milk in Tris-buffered saline containing Tween-20
(TBST, 10 mM Tris-HCl, 150 mM NaCl, 0.1% Tween-
20). For immunoblotting, the membrane was incubated
at 4°C overnight with anti-b-actin (1:1000, Keygen Bio-
tech, China), anti-CRLR (1:1000, Phoenix, USA), anti-
FAK (1:500), anti-FAK pY397 (1:500), anti-paxillin
(1:500), anti-paxillin pY118 (1:500), which were all from
Santa Cruz company (Santa Cruz, USA). Then, it was
rinsed with TBST three times and incubated with corre-
sponding horseradish peroxidase conjugated IgG antibo-
dies (1:2000, Zhongshan Golden Bridge Biotechnology,
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Beijing, China) for 2 h. Immunoreactive bands were
visualized using ECL (Beyotime Institute of Biotechnol-
ogy, Jiangsu, China). The MF-ChemiBIS 3.2 Imaging
System (DNR Bio-Imaging Systems, Israel) was used for
image capture. The optical density (OD) of each band
was measured using Image J software.
Migration assay
Cells were plated on 24 well-plates at 5 × 104/well. The
next day, cells were washed with PBS and wounds were
created by scraping with a sterilized pipette tip. After
washed twice with PBS, cells were incubated in RPMI-
1640 containing 0.5% fetal bovine serum. The wound
closure was monitored at 0-12 h. The wound areas were
observed by an inverted microscope (OlympusIX71,
Japan) and measured by Image J at the exact place and
the healing percentages were calculated. Each test was
performed triplicates.
CRLR knockdown with siRNA
The CRLR-specific small interfering RNA (siRNA)
(#42272) and scrambled siRNA (#4611) were designed and
synthesized by Ambion (USA). Using Lipofectamine 2000
(Invitrogen, CA, USA), HO8910 cells were transfected
with siRNAs following the manufacturer’s protocol. Cells
were cultured with fresh medium 6 h after transfection.
Real-time PCR
To confirm the effection of siRNA, we carried out real-
time RT-PCR by using SYBR Premix Ex Taq™ II kit
(Takara, Japan). Total RNA was extracted by RNAiso
Plus (Takara, Japan) according to the manufactor’s pro-
tocol. 2 microgram of total RNA were subjected to
cDNA synthesis by AMV transctriptase and the random
primer (Takara, Otsu, Japan). Oligonucleotide primers
for CRLR were designed as follows: forward: 5’-
GGATGGCTCTGCTGGAACGATGT -3’ and reverse:
5’-TGCAGTCTTCACTTTCTCGTGGG -3’ (204 bp).
The primers for the internal control, b-actin were for-
ward: 5’- AAGGCTGTGGGCAAGG -3’ and reverse: 5’-
TGGAGGAGTGGGTGTCG -3’ (238 bp). PCR amplifi-
cation of cDNA was performed in 20 μL mixtures con-
taining 10 μL SYBR Premix Ex Taq (×2) with 0.08 μL of
each primer, 0.4 μL of ROX Reference Dye, and 1 μL of
template cDNA (50 μg/μL). The protocol included the
following parameters: an initial 30 s of incubation at 94°
C followed by 40 cycles of denaturation at 95°C for 5 s
and annealing at 60°C for 35 s. Each experiment was
done at least in triplicate, and the gene expression levels
were calculated by ΔΔCt method.
Flow cytometer analysis
To study the cell surface expression of integrin a5 anti-
integrin a5 mAb (IIA1) (BD Biosciences, USA) were
used at the recommended concentrations [18]. Cells
were incubated with antibody for 30 min at 4°C and
washed with PBS 3 times. Then cells were incubated
with PE-conjugated IgG (1:300, Beijing Zhongshan
Golden Bridge Biotechnology Co. China) for 45 min at
4°C, washed and fixed in 2% formaldehyde. Cells immu-
nofluorescent contents were evaluated with a FACSCali-
bur flow cytometer (BD Biosciences, USA).
Statistical analysis
SPSS 16.0 software was employed for all data analysis.
Statistical evaluation was performed using the Spearman
correlation test to analyze the rank data between the
AM expression and clinicopathological parameters.
Overall and disease-free survival curves were generated
using the Kaplan-Meier method, and the differences
between the curves were assessed using the Log-rank
test. A COX proportional hazard model was used to
determine the factors related to survival time. And one-
way ANOVA was used to analyze the wound healing
rates between groups and realtime PCR results as well.
P < 0.05 was considered as statistically significant.
Results
Clinical significance of AM expression in ovarian
carcinomas
There were 96 EOC cases eligible for our study. The age
of patients ranged from 30 to 77 years (median = 52).
Of all the cases, 17 were FIGO-I ovarian carcinomas, 19
were FIGO-II stage, 53 were FIGO-III stage and 7 were
FIGO-IV stage. AM was mainly expressed in the cyto-
plasm and membrane of EOCs, seldom in nuclear of
EOC cells, and was also expressed in the endothelial
vessel cells and stromal cells in tumors, as shown in Fig-
ure 1 using immunostaining. In ovarian malignant
tumor samples, 91.67% of cases (88/96) showed AM
protein expression in the membrane and the cytoplasm
of EOCs. As shown in Table 1, AM expression was
positively correlated with FIGO stage (P = 0.003), resi-
dual tumor after initial laparotomy (P = 0.000), but not
with age, degree of differentiation, or serum CA125
before operation.
Follow-up information was available for 82 EOC
patients with survival periods ranging from 2 to 89
months (median = 36 months). Survival curves for
EOCs were stratified according to AM expression (Fig-
ure 2). By using the Kaplan-Meier method, we indi-
cated that both survival time and disease-free time for
patients were linked to AM expression status (disease-
free time, P = 0.020, Figure 2A; overall survival time, P
= 0.030, Figure 2B). By using univariate Cox propor-
tional analysis, AM expression was statistically corre-
lated to disease-free survival and overall survival (P <
0.05, Table 2). By using multivariate Cox proportional
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analysis, considering all the clinical parameters and
AM expression, FIGO staging was an independent fac-
tor of disease-free survival prognosis prediction, and
both age and disease-free time were independent fac-
tors predicted EOC over-all survival prognosis (P <
0.05, Table 3).
AM promoted ovarian cancer cells migration
HO8910 cells migration was enhanced with exogenous
AM treatment in both dose-dependent and time depen-
dent manners, as shown in Figure 3. Cell migration
rates were consequently increased when cells were trea-
ted with different dose of AM (1, 10, 100 nM) for 12 h
Figure 1 AM expression in EOC samples. Immunohistochemical analysis of AM expression in EOCs. EOCs: FIGO III stage serous (i), FIGO I stage
serous (ii), mucinous (iii), clear-cell (iv), endometrioid (v) ovarian cancer, malignant Brenner tumor of ovary (vi).
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(Figure 3A). Recovery rates were 29.23 ± 4.15% with
negative control, 43.06 ± 2.63% with 1 nM (P = 0.008),
51.58 ± 2.93% with 10 nM (P = 0.002),62.61 ± 4.51%
with 100 nM (P = 0.001), respectively. A time course
experiment was provided with AM (100 nM) by differ-
ent incubation periods (1 h, 6 h, and 12 h). And the
AM effect was increased gradually at 2 h (P = 0.023),
and reached the maximum at 12 h (P = 0.000, Figure
3B). AM22-52, the receptor antagonist of AM, inhibited
HO8910 cell migration (P = 0.024), and significantly
inhibited the effect of AM on the migration of cells (P =
0.015, Figure 3C). Previously knockdown of AM recep-
tor CRLR by siRNA effectively aborted the expression of
mRNA (P = 0.013, Figure 4A) and protein expression of
CRLR in HO8910 cells (Figure 4B). When cells were
transfected with CRLR siRNA, the effect of AM on cell
migration was decreased consequently (P = 0.001, Figure
4C).
HO8910 cells were treated with exogenous AM (100
nM) before subjecting to cell migration assay. Wound
healing percentages were measured and calculated at
time point of 3 h, 6 h, 12 h (A). Different concentration
of AM (1, 10, 100 nM) were administrated to HO8910
cells and wound healing percentages were calculated at
24 h (B). AM (22-52) inhibited HO8910 cells migration
and also antagonized the AM (100 nM) effect on migra-
tion (C). Each test was repeated triplicates
AM enhanced HO8910 cell migration was linked to the
activation of integrin a5b1 signaling pathway
By using flow cytometry, we studied the effects of AM
on the expression of integrin a5. At 12 h after providing
AM (100 nM), significant increased integrin a5 expres-
sion was observed in AM treated cells (Figure 5A). We
Table 1 Relationship between AM expression and
clinicopathological features in EOCs
Clinicopathological features n AM expression
- + ++ +++ P value
Age(years) 0.705
< 55 56 5 18 12 21
≥ 55 40 3 9 9 19
Histotype 0.155
Serous 75 7 17 17 34
Non serous 21 1 10 4 6
Residual tumor after initial laparotomy 0.000*
< 1 cm 42 1 21 10 10
≥ 1 cm 53 7 6 11 29
Undetermined 1 0 0 0 1
Differentiation 0.199
Well-differentiated 27 4 11 6 6
Moderately-differentiated 23 1 8 3 11
Poorly-differentiated 39 3 7 11 18
Undetermined 7 0 1 1 5
FIGO staging 0.003*
I 17 1 10 1 5
II 19 0 10 4 5
III 53 6 7 13 27
IV 7 1 0 3 3
Serum CA125 0.301
≥ 500 52 5 11 13 23
< 500 41 3 16 7 15
Undetermined 3 0 0 1 2
*P < 0.05
EOC = epithelial ovarian cancer; AM = Adrenomedullin; FIGO = International
Federation of Gynecology and Obstetrics
Figure 2 Correlation between AM status and EOC patient
prognosis. Kaplan-Meier curves for disease-free survival rate of EOC
patients according to the AM expression status (A); Kaplan-Meier
total survival curves of EOC patients according to the AM expression
status (B). Both survival time and disease-free time of patients were
linked to AM expression status (Log-rank test, P = 0.020; P = 0.030).
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found that the blocking antibody against integrin a5b1
effectively downregulated the cell migration promotion
effects of AM (P = 0.000, Figure 5B). We also found
that AM induced the phosphorylation of FAK and paxil-
lin. Treatment with AM (100 nM) significantly increased
the phosphorylation status of FAK 397 at 15 min time
point, and paxillin 118 at 60 min (Figure 5C). And
blocking the integrin a5b1 activity significantly inhibited
the phosphorylation of FAK and paxillin by AM (Figure
5D).
Discussion
AM is a peptide and pathologically elevated in various
tumors. We described the relationship between AM
expression and clinicopathological parameters of 96
cases of EOC with immunohistochemical analysis in the
Table 2 Univariate Cox proportional hazards regression analyses of clinicopathological variables and AM expression
for EOC patient outcome




P value Relative risk
(95%CI)
P value
Age(≥ 55 years) 1.663(0.985-2.808) 0.057 2.174(1.201-3.935) 0.010*
Differentiation 1.542(1.084-2.193) 0.016* 1.449(0.971-2.161) 0.069
FIGO staging(II-IV) 4.883(1.937-12.309) 0.001* 5.285(1.630-17.131) 0.006*
Residual tumor after
initial laparotomy (≥ 1 cm) 2.776(1.598-4.824) 0.000* 2.760(1.458-5.227) 0.002*
AM expression 1.878(1.081-3.265) 0.025* 2.014(1.052-3.852) 0.035*
Disease-free time 0.925(0.904-0.946) 0.000*
*P < 0.05, P value were calculated by Wald statistics
Table 3 Multivariate Cox proportional hazards regression analyses of clinicopathological variables and AM expression
for EOC patient outcome




P value Relative risk
(95%CI)
P value
Age(≥ 55 years) 1.663(0.983-2.813) 0.058 1.880(1.012-3.495) 0.046*
Differentiation 1.061(0.785-1.434) 0.702 0.964(0.689-1.349) 0.830
FIGO staging(II-IV) 4.886(1.938-12.322) 0.001* 0.949(0.219-4.118) 0.944
Residual tumor after
initial laparotomy (≥ 1 cm) 1.514(0.794-2.888) 0.208 1.285(0.651-2.537) 0.469
AM expression 1.307(0.735-2.324) 0.362 0.868(0.426-1.769) 0.697
Disease-free time 0.927(0.906-0.948) 0.000*
*P < 0.05, P value were calculated by Wald statistics.
CI = confidence interval.
Figure 3 Enhanced migration by AM in time-dependent and dose-dependent manners.
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present study. We found that AM expression was posi-
tively related to the FIGO stage and with residual tumor
size after initial surgical treatment. These data indicated
that expression of AM might contribute to more
aggressive behavior of EOC, and participate in EOC pro-
gression. AM high expression showed shorter disease
free time and over-all survival time, which was similar
with Hata’s research by analyzing AM mRNA expression
in 60 cases of EOCs [9]. We separately evaluated prog-
nostic value of various factors by univariate COX pro-
portional analysis, and found that AM expression was
significantly associated with both the disease free survi-
val and over-all survival. By using multivariant COX
proportional analysis which evaluated all variants
together, FIGO staging and age were independent fac-
tors of EOC prognosis prediction.
In order to further investigate the effects of AM on
EOC progression, we provided exogenous AM to EOC
cell line HO8910. The migratory rate of HO8910 was
significantly increased in AM treated groups, which
was blocked by the receptor antagonist AM22-52.
Then, we endogenously decreased the AM receptor
CRLR expression by specific siRNA, and found that
CRLR downregulation mostly blocked the positive
effect of AM on cell migration. Thus we considered
that CRLR played crucial roles in AM promoting
migration of HO8910 cells.
In this study, we also observed that AM significantly
increased integrin a5 expression by FACS analysis, indi-
cating a new signaling for AM function. Antibodies of
integrin a5b1 were mainly used to anti-tumors treat-
ment [19,20], especially for the advanced platinum-resis-
tance EOCs [21]. In this study, the blocking antibody
was used to illustrate whether integrin a5b1 was
involved in AM induced cell migration. We found that
cell migratory rate was decreased in integrin a5b1 anti-
body pretreated group compared to single AM treated
cells. Also, factors associated with integrin a5b1 were
analyzed in our study. Integrin a5b1 could consequently
activate many cytoskeleton proteins by binding to FN,
of which FAK and paxillin were crucial members
[22-24]. It was shown that FAK phosphorylation was
required for integrin stimulated cell migration by creat-
ing a binding site for the Src kinase family. FAK could
also phosphorylate paxillin by in vitro and in vivo stu-
dies [25,26]. Paxillin was a cytoskeletal component
involved in integrin signals integration and dissemina-
tion. Phosphorylation of paxillin greatly enhanced its
function during cell migration [27,28]. Our study
showed that exogenous AM treatment enhanced phos-
phorylation of FAK Tyr397 and paxillin Tyr118. The
blocking antibody for integrin a5b1 mostly inhibited the
AM induced upregulation of FAK and paxillin phos-
phorylation as well. Therefore, in our research, AM pro-
moted HO8910 cells migration probably by upregulating
expression of integrin a5b1 and increasing FAK and
paxillin phosphorylation. However, the mechanisms of
AM affection on integrin a5b1 needs further
Figure 4 Down-regulation of CRLR expression in HO8910 cells
inhibited influence of exogenous AM on cell migration.
Reduced CRLR mRNA expression (A) and protein expression (B)
were determined by real-time PCR analysis or western blot in CRLR
siRNA transfected cells, compared with scrambled siRNA transfected
cells. After cells were transfected by CRLR siRNA, the effect of AM
on cells migration was decreased consequently (C).
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investigation, which might be owing to the enhanced
integrin-binding function of talin by AM [29].
Conclusions
In the summary, we found that high expression of AM
contributed to the progression of EOC and indicated
poorer prognosis of EOC patients, which further
demonstrated its contribution to EOC metastasis prob-
ably via integrin a5b1 mediated cell migration. All of
which suggested that AM might play great roles during
EOC cell migration, and might be considered as an
EOC therapeutic target.
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